Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established Tumors
Open Access
- 15 May 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (10), 4319-4326
- https://doi.org/10.1158/0008-5472.can-08-3141
Abstract
Vaccines represent an attractive treatment modality for the management of cancer primarily because of their specificity and generation of immunologic memory important for controlling recurrences. However, the efficacy of therapeutic vaccines may require formulations that not only generate effective immune responses but also overcome immune evasion mechanisms employed by progressing tumor. Costimulatory molecules play critical roles in modulating innate, adaptive, and regulatory immunity and have potential to serve as effective immunomodulatory components of therapeutic vaccines. In this study, we tested the function of a novel soluble form of 4-1BB ligand (4-1BBL) costimulatory molecule in modulating innate, adaptive, and regulatory immunity and assessed its therapeutic efficacy in the HPV-16 E7-expressing TC-1 cervical cancer and survivin-expressing 3LL lung carcinoma mouse models. Vaccination with 4-1BBL activated dendritic cells and enhanced antigen uptake, generated CD8+ T-cell effector/memory responses, and endowed T effector cells refractory to suppression by CD4+CD25+FoxP3+ T regulatory cells. Immunization with 4-1BBL in combination with an E7 peptide or survivin protein resulted in eradication of TC-1 and 3LL tumors, respectively. 4-1BBL was more effective than TLR agonists LPS, MPL, and CpG and an agonistic 4-1BB antibody as a component of E7 peptide-based therapeutic vaccine for the generation of immune responses and eradication of TC-1 established tumors in the absence of detectable toxicity. Therapeutic efficacy was associated with reversal of tumor-mediated nonresponsiveness/anergy as well as establishment of long-term CD8+ T-cell memory. Potent pleiotropic immunomodulatory activities combined with lack of toxicity highlight the potential of 4-1BBL molecule as an effective component of therapeutic cancer vaccines. [Cancer Res 2009;69(10):4319–26]Keywords
Other Versions
This publication has 42 references indexed in Scilit:
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejectionThe Journal of Experimental Medicine, 2008
- A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903Annals of Surgical Oncology, 2007
- Cooperation of Toll-like receptor signals in innate immune defenceNature Reviews Immunology, 2007
- Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cellsInternational Immunology, 2005
- Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulationTrends in Immunology, 2005
- TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)Vaccine, 2005
- Cell Membrane Modification for Rapid Display of Proteins as a Novel Means of ImmunomodulationImmunity, 2002
- In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responsesNature Immunology, 2002
- Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantationTransplantation and Cellular Therapy, 2001
- The Immunological Synapse: A Molecular Machine Controlling T Cell ActivationScience, 1999